• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/8/21 10:15:35 AM ET
    $ALNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNA alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 4 ALLENA PHARMACEUTICALS INC COMMON STOCK Cusip #018119107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #018119107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 2,296,083 Item 8: 0 Item 9: 2,296,083 Item 11: 4.584% Item 12: HC Cusip #018119107 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,296,083 Item 8: 0 Item 9: 2,296,083 Item 11: 4.584% Item 12: IN Item 1(a). Name of Issuer: ALLENA PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: ONE NEWTON EXECUTIVE PARK, SUITE 202 Newton, MA 02462 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 018119107 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 2,296,083 (b) Percent of Class: 4.584% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 2,296,083 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ALLENA PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of ALLENA PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 5, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 5, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ALLENA PHARMACEUTICALS INC at December 31, 2020. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.
    Get the next $ALNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALNA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease

      NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to treat metabolic diseases, today reported completion of enrollment of the first two cohorts of its ALLN-346 Phase 2a Study 202 in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disease (CKD). ALLN-346, which has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), is a first-in-class, non-absorbed, orally administered enzyme in development for the tr

      7/19/22 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for the

      7/12/22 4:05:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting, which was scheduled for July 5, 2022, to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The date of the rescheduled special meeting, and the new record date for determining the

      7/5/22 7:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Financials

    Live finance-specific insights

    See more
    • Allena Pharmaceuticals Provides Clinical and Corporate Update

      ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety profile in first cohort of patients with hyperuricemia and chronic kidney disease in the Phase 2a Study 201 Allena to host webinar to discuss the initial Study 201 data with Key Opinion Leaders Robert Terkeltaub, M.D. and David S. Goldfarb, M.D. today at 8:00 am ET; log-in information belowALLN-346 Phase 2a Study 202 is actively enrolling patients with gout and stages 2 and 3 chronic kidney disease in parallel cohorts; data from both cohorts expected in Q1 2022Company currently evaluating potenti

      1/4/22 5:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

      NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfact

      12/1/20 9:47:45 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering

      NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to sa

      12/1/20 5:00:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Katz Richard D

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      2/2/22 4:15:22 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brenner Louis Md

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      2/2/22 4:15:11 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Brenner Louis Md sold $32,666 worth of shares (40,328 units at $0.81) and converted options into 125,582 shares (tax withholding)

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      11/17/21 5:00:29 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for the

      7/12/22 4:05:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO

      - Versantis establishes wholly-owned U.S. subsidiary, Versantis, Inc. - - Current CEO, Vincent Forster, to maintain his key role as Chief Scientific Officer - Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, today announced the appointment of Mark J. Fitzpatrick as Chief Executive Officer (CEO) and member of the board of directors, effective January 1, 2022. He joins Versantis with more than 25 years of experience in the biopharma industry, primarily in senior executive roles, and will be based in the U.S. following the establishment of Versantis, Inc. He succeeds co-founder Dr. Vincent Forster, who will assume the role

      12/20/21 1:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors Allena Pharmaceuticals, Inc.

      NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors. “Mark is an experienced industry executive, who has led financial strategy at biopharmaceutical companies across all stages of development,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “His extensive experience working with late-stage, rare disease companies will be particular

      4/7/21 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    SEC Filings

    See more
    • SEC Form SEC STAFF ACTION filed by Allena Pharmaceuticals Inc.

      SEC STAFF ACTION - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      6/12/23 2:00:02 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Allena Pharmaceuticals Inc.

      NT 10-Q - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      11/14/22 4:03:10 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Allena Pharmaceuticals Inc.

      25-NSE - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      9/14/22 9:52:49 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      2/14/23 4:09:01 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      2/14/22 4:34:57 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      1/28/22 1:42:29 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care